---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-068055"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:33:45.444394+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eyenovia updates corporate presentation; MicroPine interim readout 4Q 2024, Clobetasol launch 3Q 2024

## Summary
- MicroPine Phase 3 CHAPERONE interim DMC review expected 4Q 2024; SAE rate <1 per 1,000 patient-months, all unrelated.
- Clobetasol propionate 0.05% launch expected 3Q 2024; projected 3rd-year sales $50M; co-promotion with NovaBay for Avenova.
- Optejet Gen-2 FDA meeting planned 3Q 2024 to confirm pathway for drug/device; licensing targets dry eye and glaucoma (>$8.8B market).
- MicroPine potential peak US sales >$1B by 2036; net price $200/month, COGS <$20; addresses ~5M high-risk myopic children.
- Optecare digital compliance system built into Optejet to track adherence; aims to improve patient outcomes and differentiate.

## SEC filing metadata
- accession: 0001104659-24-068055
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465924068055/0001104659-24-068055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465924068055/tm2416348d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-068055
- JSON: https://secwatch.observer/filing/0001104659-24-068055.json
- Plain text: https://secwatch.observer/filing/0001104659-24-068055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.